Literature DB >> 21493890

Dimethylarginine dimethylaminohydrolase-1 is the critical enzyme for degrading the cardiovascular risk factor asymmetrical dimethylarginine.

Xinli Hu1, Dorothee Atzler, Xin Xu, Ping Zhang, Haipeng Guo, Zhongbing Lu, John Fassett, Edzard Schwedhelm, Rainer H Böger, Robert J Bache, Yingjie Chen.   

Abstract

OBJECTIVE: The objective of this study was to identify the role of dimethylarginine dimethylaminohydrolase-1 (DDAH1) in degrading the endogenous nitric oxide synthase inhibitors asymmetrical dimethylarginine (ADMA) and N(g)-monomethyl-L-arginine (L-NMMA). METHODS AND
RESULTS: We generated a global-DDAH1 gene-deficient (DDAH1(-/-)) mouse strain to examine the role of DDAH1 in ADMA and l-NMMA degradation and the physiological consequences of loss of DDAH1. Plasma and tissue ADMA and L-NMMA levels in DDAH1(-/-) mice were several folds higher than in wild-type mice, but growth and development of these DDAH1(-/-) mice were similar to those of their wild-type littermates. Although the expression of DDAH2 was unaffected, DDAH activity was undetectable in all tissues tested. These findings indicate that DDAH1 is the critical enzyme for ADMA and L-NMMA degradation. Blood pressure was ≈ 20 mm Hg higher in the DDAH1(-/-) mice than in wild-type mice, but no other cardiovascular phenotype was found under unstressed conditions. Crossing DDAH1(+/-) male with DDAH1(+/-) female mice yielded DDAH1(+/+), DDAH1(+/-), and DDAH1(-/-) mice at the anticipated ratio of 1:2:1, indicating that DDAH1 is not required for embryonic development in this strain.
CONCLUSIONS: Our findings indicate that DDAH1 is required for metabolizing ADMA and L-NMMA in vivo, whereas DDAH2 had no detectable role for degrading ADMA and l-NMMA.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21493890      PMCID: PMC3117037          DOI: 10.1161/ATVBAHA.110.222638

Source DB:  PubMed          Journal:  Arterioscler Thromb Vasc Biol        ISSN: 1079-5642            Impact factor:   8.311


  45 in total

1.  Reduced urinary excretion of nitric oxide metabolites and increased plasma levels of asymmetric dimethylarginine in men with essential hypertension.

Authors:  A Surdacki; M Nowicki; J Sandmann; D Tsikas; R H Boeger; S M Bode-Boeger; O Kruszelnicka-Kwiatkowska; F Kokot; J S Dubiel; J C Froelich
Journal:  J Cardiovasc Pharmacol       Date:  1999-04       Impact factor: 3.105

2.  Reversible inhibition of cytochrome c oxidase, the terminal enzyme of the mitochondrial respiratory chain, by nitric oxide. Implications for neurodegenerative diseases.

Authors:  M W Cleeter; J M Cooper; V M Darley-Usmar; S Moncada; A H Schapira
Journal:  FEBS Lett       Date:  1994-05-23       Impact factor: 4.124

3.  Identification of two human dimethylarginine dimethylaminohydrolases with distinct tissue distributions and homology with microbial arginine deiminases.

Authors:  J M Leiper; J Santa Maria; A Chubb; R J MacAllister; I G Charles; G S Whitley; P Vallance
Journal:  Biochem J       Date:  1999-10-01       Impact factor: 3.857

4.  Overexpression of dimethylarginine dimethylaminohydrolase reduces tissue asymmetric dimethylarginine levels and enhances angiogenesis.

Authors:  Johannes Jacobi; Karsten Sydow; Georges von Degenfeld; Ying Zhang; Hayan Dayoub; Bingyin Wang; Andrew J Patterson; Masumi Kimoto; Helen M Blau; John P Cooke
Journal:  Circulation       Date:  2005-03-22       Impact factor: 29.690

5.  Dimethylarginine dimethylaminohydrolase and endothelial dysfunction in failing hearts.

Authors:  YingJie Chen; Yunfang Li; Ping Zhang; Jay H Traverse; Mingxiao Hou; Xin Xu; Masumi Kimoto; Robert J Bache
Journal:  Am J Physiol Heart Circ Physiol       Date:  2005-07-15       Impact factor: 4.733

6.  Nephrogenic diabetes insipidus in mice lacking all nitric oxide synthase isoforms.

Authors:  Tsuyoshi Morishita; Masato Tsutsui; Hiroaki Shimokawa; Ken Sabanai; Hiromi Tasaki; Osamu Suda; Sei Nakata; Akihide Tanimoto; Ke-Yong Wang; Yoichi Ueta; Yasuyuki Sasaguri; Yasuhide Nakashima; Nobuyuki Yanagihara
Journal:  Proc Natl Acad Sci U S A       Date:  2005-07-15       Impact factor: 11.205

7.  Determination of asymmetric dimethylarginine (ADMA) using a novel ELISA assay.

Authors:  Friedrich Schulze; Reinhard Wesemann; Edzard Schwedhelm; Karsten Sydow; Jennifer Albsmeier; John P Cooke; Rainer H Böger
Journal:  Clin Chem Lab Med       Date:  2004       Impact factor: 3.694

8.  Hypertension in mice lacking the gene for endothelial nitric oxide synthase.

Authors:  P L Huang; Z Huang; H Mashimo; K D Bloch; M A Moskowitz; J A Bevan; M C Fishman
Journal:  Nature       Date:  1995-09-21       Impact factor: 49.962

9.  Nanomolar concentrations of nitric oxide reversibly inhibit synaptosomal respiration by competing with oxygen at cytochrome oxidase.

Authors:  G C Brown; C E Cooper
Journal:  FEBS Lett       Date:  1994-12-19       Impact factor: 4.124

10.  Increased endogenous nitric oxide synthase inhibitor in patients with congestive heart failure.

Authors:  M Usui; H Matsuoka; H Miyazaki; S Ueda; S Okuda; T Imaizumi
Journal:  Life Sci       Date:  1998       Impact factor: 5.037

View more
  53 in total

1.  Pulmonary hypertension associated with advanced systolic heart failure: dysregulated arginine metabolism and importance of compensatory dimethylarginine dimethylaminohydrolase-1.

Authors:  Zhili Shao; Zeneng Wang; Kevin Shrestha; Akanksha Thakur; Allen G Borowski; Wendy Sweet; James D Thomas; Christine S Moravec; Stanley L Hazen; W H Wilson Tang
Journal:  J Am Coll Cardiol       Date:  2012-03-27       Impact factor: 24.094

Review 2.  Asymmetric dimethylarginine (ADMA) as an important risk factor for the increased cardiovascular diseases and heart failure in chronic kidney disease.

Authors:  Xiaohong Liu; Xin Xu; Ruru Shang; Yingjie Chen
Journal:  Nitric Oxide       Date:  2018-06-19       Impact factor: 4.427

3.  DDAH says NO to ADMA.

Authors:  John P Cooke; Yohannes T Ghebremariam
Journal:  Arterioscler Thromb Vasc Biol       Date:  2011-07       Impact factor: 8.311

Review 4.  Asymmetric dimethylarginine and reactive oxygen species: unwelcome twin visitors to the cardiovascular and kidney disease tables.

Authors:  Christopher S Wilcox
Journal:  Hypertension       Date:  2012-01-03       Impact factor: 10.190

Review 5.  Effect of asymmetric dimethylarginine (ADMA) on heart failure development.

Authors:  Xiaoyu Liu; Lei Hou; Dachun Xu; Angela Chen; Liuqing Yang; Yan Zhuang; Yawei Xu; John T Fassett; Yingjie Chen
Journal:  Nitric Oxide       Date:  2016-02-24       Impact factor: 4.427

6.  Cardiomyocyte dimethylarginine dimethylaminohydrolase-1 (DDAH1) plays an important role in attenuating ventricular hypertrophy and dysfunction.

Authors:  Xin Xu; Ping Zhang; Dongmin Kwak; John Fassett; Wenhui Yue; Dorothee Atzler; Xinli Hu; Xiaohong Liu; Huan Wang; Zhongbing Lu; Haipeng Guo; Edzard Schwedhelm; Rainer H Böger; Peijie Chen; Yingjie Chen
Journal:  Basic Res Cardiol       Date:  2017-08-17       Impact factor: 17.165

Review 7.  Nitric oxide synthase derangements and hypertension in kidney disease.

Authors:  Chris Baylis
Journal:  Curr Opin Nephrol Hypertens       Date:  2012-01       Impact factor: 2.894

8.  Dissection, Optimization, and Structural Analysis of a Covalent Irreversible DDAH1 Inhibitor.

Authors:  Gayle Burstein-Teitelbaum; Joyce A V Er; Arthur F Monzingo; Alfred Tuley; Walter Fast
Journal:  Biochemistry       Date:  2018-07-20       Impact factor: 3.162

9.  Developing an irreversible inhibitor of human DDAH-1, an enzyme upregulated in melanoma.

Authors:  Yun Wang; Shougang Hu; Abdul M Gabisi; Joyce A V Er; Arthur Pope; Gayle Burstein; Christopher L Schardon; Arturo J Cardounel; Suhendan Ekmekcioglu; Walter Fast
Journal:  ChemMedChem       Date:  2014-02-26       Impact factor: 3.466

10.  FXR agonist INT-747 upregulates DDAH expression and enhances insulin sensitivity in high-salt fed Dahl rats.

Authors:  Yohannes T Ghebremariam; Keisuke Yamada; Jerry C Lee; Christine L C Johnson; Dorothee Atzler; Maike Anderssohn; Rani Agrawal; John P Higgins; Andrew J Patterson; Rainer H Böger; John P Cooke
Journal:  PLoS One       Date:  2013-04-04       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.